Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Eija Riitta Salomaa"'
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Currently, two disease-modifying antifibrotic drugs are indicated for the treatment of idiopathic pulmonary fibrosis. The objective of this study was to analyse antifibrotic and overall prescription medication use of IPF patients
Externí odkaz:
https://doaj.org/article/4d0f33e6653f448fb9381c45fd895b48
Autor:
Jaana Kaunisto, Eija-Riitta Salomaa, Ulla Hodgson, Riitta Kaarteenaho, Hannu Kankaanranta, Katri Koli, Tero Vahlberg, Marjukka Myllärniemi
Publikováno v:
ERJ Open Research, Vol 5, Iss 3 (2019)
Idiopathic pulmonary fibrosis (IPF) is characterised by unpredictable disease course and poor survival. After the introduction of novel antifibrotic drugs, the prognosis of patients with IPF is probably changing. FinnishIPF, a nationwide registry of
Externí odkaz:
https://doaj.org/article/7c5a7c66c58143ce821d8e953509d963
Background Currently, two disease-modifying antifibrotic drugs are indicated for the treatment of idiopathic pulmonary fibrosis. The objective of this study was to analyse antifibrotic and overall prescription medication use of IPF patients in the re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eee3086bda3b86c22aeeebf461ef5109
https://doi.org/10.21203/rs.3.rs-2743387/v1
https://doi.org/10.21203/rs.3.rs-2743387/v1
Publikováno v:
European Clinical Respiratory Journal, Vol 4, Iss 1 (2017)
Background: The early diagnosis of idiopathic pulmonary fibrosis (IPF) has become increasingly important due to evolving treatment options. IPF patients experience a significant delay in receiving an accurate diagnosis, thus delayed access to tertiar
Externí odkaz:
https://doaj.org/article/85626d7e85564a5fa4020b591b721df3
Autor:
Hannu Kankaanranta, Eija-Riitta Salomaa, Katri Koli, Riitta Kaarteenaho, Ulla Hodgson, Tero Vahlberg, Jaana Kaunisto, Marjukka Myllärniemi
Publikováno v:
ERJ Open Research, Vol 5, Iss 3 (2019)
ERJ Open Research
ERJ Open Research
Idiopathic pulmonary fibrosis (IPF) is characterised by unpredictable disease course and poor survival. After the introduction of novel antifibrotic drugs, the prognosis of patients with IPF is probably changing. FinnishIPF, a nationwide registry of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::408a496a8e3bb18ddd93fa7a7bd83a51
http://hdl.handle.net/10138/313003
http://hdl.handle.net/10138/313003
Publikováno v:
European Clinical Respiratory Journal, Vol 4, Iss 1 (2017)
European Clinical Respiratory Journal
European Clinical Respiratory Journal
Background: The early diagnosis of idiopathic pulmonary fibrosis (IPF) has become increasingly important due to evolving treatment options. IPF patients experience a significant delay in receiving an accurate diagnosis, thus delayed access to tertiar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ccfe02ef3b9ee0ce5f2f76c5f175d45
https://doaj.org/article/85626d7e85564a5fa4020b591b721df3
https://doaj.org/article/85626d7e85564a5fa4020b591b721df3
Publikováno v:
The Clinical Respiratory Journal. 6:96-103
Introduction: Pemetrexed has emerged as standard chemotherapy for malignant pleural mesothelioma (MPM). Objectives: MPMs at two Finnish University Hospitals during 7 years (2000–2006) were reviewed in order to evaluate the treatments, survival and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d8aa17b4ee1c439fb3ca3b232ec8706
https://doi.org/10.1111/j.1752-699x.2011.00252.x
https://doi.org/10.1111/j.1752-699x.2011.00252.x
Publikováno v:
1.5 Diffuse Parenchymal Lung Disease.
The early diagnosis of idiopathic pulmonary fibrosis (IPF) is important due to improved treatment options. We have evaluated the quality of referral letters sent to tertiary care by primary health care physicians in relation to the recognition of IPF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adca2978cad1170da6c3b2908112e811
https://doi.org/10.1183/13993003.congress-2015.pa2045
https://doi.org/10.1183/13993003.congress-2015.pa2045
Autor:
Eija-Riitta, Salomaa, Maija, Walta
Publikováno v:
Duodecim; laaketieteellinen aikakauskirja. 131(1)
The survival of lung cancer patients is still poor; 10-15% are alive five years after diagnosis.We evaluated 1 542 patients with new lung cancer diagnosis in 2004-2011.The one-, two- and five-year survival rate was 37.3%, 23.3% and 10.5%, respectivel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::36fcec03253b293a9e7dc0ed9aa8d6fc
https://pubmed.ncbi.nlm.nih.gov/26245058
https://pubmed.ncbi.nlm.nih.gov/26245058
Autor:
Eija-Riitta, Salomaa, Minna, Myllylä, Ulla, Anttalainen, Tarja, Laitinen, Samu, Kurki, Jussi, Virkkala, Tarja, Saaresranta
Publikováno v:
Duodecim; laaketieteellinen aikakauskirja. 129(20)
We evaluated the changes in nasal CPAP treatment and adherence in patients with sleep-disordered breathing (SDB).Information from the clinic database of 4,385 patients commencing CPAP treatment during 2002-2009.Average CPAP adherence was 74%. In mild
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::da8c078062abaaa15d44b51f0c593cd5
https://pubmed.ncbi.nlm.nih.gov/24340719
https://pubmed.ncbi.nlm.nih.gov/24340719